CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02420717
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:42.686441+00:00
Published At: 2022-05-02T00:00:00+00:00
Record Updated At: 2025-06-08
Results Posted At: 2022-05-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Ph-Like Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Ph-Like Acute Lymphoblastic Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-08"
protocolSection.identificationModule.nctId: "NCT02420717"
protocolSection.identificationModule.officialTitle: "A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-05-02"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.